论文部分内容阅读
目的:观察加味瓜蒌散对门脉高压大鼠胃肠激素、纤维化的影响。方法:采用CCl4加酒精饮料制作大鼠门脉高压模型,造模4周后分别给大鼠服用加味瓜蒌散、心得安,造模结束后处死大鼠,颈动脉取血,用放免法检测正常组、模型组、心得安治疗组、加味瓜蒌散治疗组血浆中胃肠激素(胃动素、胃泌素、胰高血糖素)、纤维化的含量。结果:心得安组胃动素含量与模型组比较无明显改善(P>0.05),而胃泌素、胰高血糖素明显下降(P<0.05)。加味瓜蒌散治疗组胃泌素、胃动素、胰高血糖素含量与模型组比较明显下降(P<0.01或0.05),与心得安治疗比较胃动素、胰高血糖素下降明显(P<0.05),加味瓜蒌散各剂量组之间差异无统计学意义。加味瓜蒌散各剂量组CIV、PCⅢ、HA、LN与模型组比较均明显下降(P<0.01或0.05),而心得安组CIV、LN、PCⅢ与模型组比较差异无统计学意义(P>0.05),HA明显升高(P<0.05)。结论:加味瓜蒌散能有效降低胃泌素、胃动素、胰高血糖素含量及肝纤维化,优于心得安治疗组。
Objective: To observe the effect of Modified Gualou Powder on gastrointestinal hormones and fibrosis in rats with portal hypertension. METHODS: Rat portal hypertension models were made using CCl4 and alcoholic beverages. After 4 weeks of modeling, the rats were given Guwei Powder and Propranolol, respectively. After the model was completed, rats were sacrificed. Blood was taken from the carotid artery and tested by radioimmunoassay. The levels of plasma gastrointestinal hormones (motilin, gastrin, glucagon) and fibrosis in the normal group, the model group, the propranolol treatment group, and the Jiawei Guayusan treatment group. Results: Compared with the model group, motilin content in the propranolol group was not significantly improved (P>0.05), but gastrin and glucagon were significantly decreased (P<0.05). The content of gastrin, motilin and glucagon in the Modified Gualou Powder group was significantly lower than that in the model group (P<0.01 or 0.05). Compared with propranolol, motilin and glucagon decreased significantly (P<0.05). <0.05), There was no significant difference between the different dosage groups of Modified Gualou Powder. Compared with the model group, the CIV, PCIII, HA, and LN levels in the modified Gualou Powder group decreased significantly (P<0.01 or 0.05), while there was no significant difference between the CIV, LN, and PCIII groups in the propranolol group and the model group (P> 0.05), HA was significantly higher (P<0.05). Conclusion: Jiawei Gualou Powder can effectively reduce gastrin, motilin, glucagon content and liver fibrosis, and is superior to propranolol treatment group.